Cargando…

Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may present risk to patients treated with donor-derived microbiome therapies when appropriate manufacturing controls and inactivation processes are lacking. We report that the manufacturing steps for SER-109, a purified investigational mic...

Descripción completa

Detalles Bibliográficos
Autores principales:	McChalicher, Christopher, Abdulaziz, Ahmad, Zhou, S Steve, Lombardo, Mary-Jane, Hasson, Brooke, Auniņš, John G, McGovern, Barbara H, Ege, David S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492665/ https://www.ncbi.nlm.nih.gov/pubmed/36158136 http://dx.doi.org/10.1093/ofid/ofac448

Ejemplares similares

1035. Manufacturing Processes of SER-109, a Purified Investigational Microbiome Therapeutic, Reduce Risk of Transmission of Emerging and Undetected Infections in Donor Stool
por: McChalicher, Christopher, et al.
Publicado: (2021)

Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool
por: McChalicher, Christopher W J, et al.
Publicado: (2023)

Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection
por: McGovern, Barbara, et al.
Publicado: (2021)

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
por: Khanna, Sahil, et al.
Publicado: (2022)

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
por: McGovern, Barbara H, et al.
Publicado: (2020)

Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI
por: Sims, Matthew, et al.
Publicado: (2023)

Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection
por: Cohen, Stuart, et al.
Publicado: (2022)

655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection
por: Kelly, Colleen R, et al.
Publicado: (2023)

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023)

1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes
por: Ford, Christopher, et al.
Publicado: (2018)

653. Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI)
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner
por: Henn, Matthew, et al.
Publicado: (2018)

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial
por: Garey, Kevin W., et al.
Publicado: (2023)

Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)
por: Henn, Matthew, et al.
Publicado: (2017)

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial
por: Sims, Matthew D., et al.
Publicado: (2023)

19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial
por: Hohmann, Elizabeth, et al.
Publicado: (2021)

A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis
por: Henn, Matthew R., et al.
Publicado: (2021)

MB109 as bioactive human bone morphogenetic protein-9 refolded and purified from E. coli inclusion bodies
por: Kuo, Mario Meng-Chiang, et al.
Publicado: (2014)

Draft Genome Sequences from Cyclospora cayetanensis Oocysts Purified from a Human Stool Sample
por: Qvarnstrom, Yvonne, et al.
Publicado: (2015)

Changes in the stool and oropharyngeal microbiome in obsessive-compulsive disorder
por: Domènech, Laura, et al.
Publicado: (2022)

1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile Infection (CDI)
por: Ford, Christopher, et al.
Publicado: (2019)

Cell-Based Manufacturing Technology Increases Antigenic Match of Influenza Vaccine and Results in Improved Effectiveness
por: Rockman, Steven, et al.
Publicado: (2022)

Optimal screening and donor management in a public stool bank
por: Kazerouni, Abbas, et al.
Publicado: (2015)

An Exploration of the Psycho-Social Benefits of Providing Sponsorship and Supporting Others in Traditional 12 Step, Self-Help Groups
por: McGovern, William, et al.
Publicado: (2021)

New statistical method identifies cytokines that distinguish stool microbiomes
por: Yang, Dake, et al.
Publicado: (2019)

In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation
por: McSweeney, Breanna, et al.
Publicado: (2019)

Clinical evaluation of a non-purified direct molecular assay for the detection of Clostridioides difficile toxin genes in stool specimens
por: Hara, Toshinori, et al.
Publicado: (2020)

The design and manufacture of 3D‐printed adjuncts for powered air‐purifying respirators
por: Miles, L. F., et al.
Publicado: (2020)

Microbiome Analysis of Stool Samples from African Americans with Colon Polyps
por: Brim, Hassan, et al.
Publicado: (2013)

Genome-Resolved Characterization of Structure and Potential Functions of the Zebrafish Stool Microbiome
por: Kayani, Masood ur Rehman, et al.
Publicado: (2022)

Q-value for the positron decay of $^{109}$Sb and the level scheme of $^{109}$Sn
por: Johnston, M G, et al.
Publicado: (1981)

16S rRNA sequencing of samples from universal stool bank donors
por: Santiago, Marina, et al.
Publicado: (2021)

A comprehensive approach to stool donor screening for faecal microbiota transplantation in China
por: He, Jianquan, et al.
Publicado: (2021)

Thriving in the gig economy: how to capitalize and compete in the new world of work
por: McGovern, Marion
Publicado: (2017)

Taking a Bite Out of Amalgam Concerns?: Study Shows No Renal Effects in Children
por: McGovern, Victoria
Publicado: (2008)

A Twist in the Ritalin Riddle: Drug-Related Genomic Damage Not Confirmed in Children
por: McGovern, Victoria
Publicado: (2007)

Signs for Girls: Biomarkers of Common Exposures
por: McGovern, Victoria
Publicado: (2007)

Aging: Shedding Light on Vitamin D Deficiency in Women
por: McGovern, Victoria
Publicado: (2004)

Spraying on a Summer Night: A Safer Way to Stop West Nile Virus
por: McGovern, Victoria
Publicado: (2004)

Asthma: Bowled Over by Dust
por: McGovern, Victoria
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_n2rblhkcu7q7cqeb53e8kh90io